WO2022134260A1 - 胆绿素或其衍生物的制备方法 - Google Patents
胆绿素或其衍生物的制备方法 Download PDFInfo
- Publication number
- WO2022134260A1 WO2022134260A1 PCT/CN2021/073781 CN2021073781W WO2022134260A1 WO 2022134260 A1 WO2022134260 A1 WO 2022134260A1 CN 2021073781 W CN2021073781 W CN 2021073781W WO 2022134260 A1 WO2022134260 A1 WO 2022134260A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- biliverdin
- formula
- derivative
- compound represented
- preparation
- Prior art date
Links
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 title claims abstract description 46
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 title claims abstract description 46
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 81
- 238000000034 method Methods 0.000 claims abstract description 22
- -1 p-toluenesulfonyl Chemical group 0.000 claims abstract description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
- 239000001257 hydrogen Substances 0.000 claims abstract description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 43
- 239000002904 solvent Substances 0.000 claims description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical class CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 7
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 claims description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 5
- 150000007530 organic bases Chemical group 0.000 claims description 5
- 239000008096 xylene Substances 0.000 claims description 5
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 150000002431 hydrogen Chemical group 0.000 claims description 3
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical class O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 3
- 150000001555 benzenes Chemical class 0.000 claims description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 17
- 238000003786 synthesis reaction Methods 0.000 abstract description 15
- 239000000047 product Substances 0.000 abstract description 8
- UYHZQOJAPATOSQ-UHFFFAOYSA-N alpha-Biliverdin-dimethylester Natural products COC(=O)CCC1=C(C)C(=N/C/1=Cc2[nH]c(C=C3/NC(=O)C(=C3C=C)C)c(C)c2CCC(=O)OC)C=C4/NC(=O)C(=C4C)C=C UYHZQOJAPATOSQ-UHFFFAOYSA-N 0.000 abstract description 4
- XAMHKORMKJIEFW-AYTKPMRMSA-N hexadecyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/C[C@H](O)CCCCCC XAMHKORMKJIEFW-AYTKPMRMSA-N 0.000 abstract description 4
- 238000009776 industrial production Methods 0.000 abstract description 4
- 239000006227 byproduct Substances 0.000 abstract description 2
- 238000004440 column chromatography Methods 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 239000007787 solid Substances 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000002253 acid Substances 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 17
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 239000011734 sodium Substances 0.000 description 11
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 150000003278 haem Chemical class 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- BPYKTIZUTYGOLE-UHFFFAOYSA-N billirubin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(C=C3C(=C(C=C)C(=O)N3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- ZVAPMHAIALHXOG-UHFFFAOYSA-N 3-methyl-4-[2-(4-methylphenyl)sulfanylethyl]-2-(4-methylphenyl)sulfonyl-1,2-dihydropyrrol-5-one Chemical compound O=C1NC(S(=O)(=O)C=2C=CC(C)=CC=2)C(C)=C1CCSC1=CC=C(C)C=C1 ZVAPMHAIALHXOG-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108050006318 Haem oxygenases Proteins 0.000 description 1
- 102000016761 Haem oxygenases Human genes 0.000 description 1
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- PLBQLIFDSMCQBT-UHFFFAOYSA-N methyl 3-(5-formyl-4-methyl-1h-pyrrol-3-yl)propanoate Chemical compound COC(=O)CCC1=CNC(C=O)=C1C PLBQLIFDSMCQBT-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- WVEOSJLLKNIUFL-UHFFFAOYSA-N methyl propanoate Chemical compound CCC(=O)OC.CCC(=O)OC WVEOSJLLKNIUFL-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011909 oxidative ring-opening Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N p-toluenesulfonic acid Substances CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000012450 pharmaceutical intermediate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0201—Oxygen-containing compounds
- B01J31/0204—Ethers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
- B01J31/0235—Nitrogen containing compounds
Definitions
- the patent of the present invention belongs to the field of drug synthesis, and more particularly, the present invention relates to a preparation method of biliverdin or a derivative thereof.
- Biliverdin is a tetrapyrrole ring substance obtained by the hydrolysis of heme by heme oxygenase (hemeoxygenase-1, HO-1) and ring-opening (its structure is shown in formula 8). Named for its dark green color. Biliverin is not only an intermediate metabolite of the heme metabolism circulatory system, it can also initiate physiological effects such as anti-inflammatory and immune regulation, such as improving liver function, reducing alanine aminotransferase, and reducing ischemia-reperfusion caused by liver transplantation. Injury, inhibition of vascular remodeling by neovascular intima formation, and inhibition of bovine diarrhea virus replication and other functions. Therefore, biliverdin has great potential for clinical drug use.
- Bilirubin IX ⁇ is the main raw material for in vitro cultivation of bezoar. Biliverin IX ⁇ can be used to prepare bilirubin IX ⁇ (CN2018113118011.9). Biliverin IX ⁇ is also an important pharmaceutical intermediate.
- the preparation of biliverdin mainly includes extraction method, chemical conversion method, enzymatic conversion method and biosynthesis method.
- the extraction method has a very limited source of raw materials, and in addition, various isomers are easily formed during the extraction process of bilirubin, resulting in low yield and purity of the product bilirubin. It is reported that the method also produces more isomers, and the yield is low; there are currently reports on the conversion of biliverdin from heme by enzymatic conversion and biosynthesis, but the oxidative ring-opening selectivity is not high, and the source of heme Limited, high price, and not suitable for industrial production.
- the present invention aims to solve one of the technical problems existing in the prior art at least to a certain extent, for this purpose, the present invention provides a preparation method of biliverdin or a derivative thereof, wherein the biliverdin or a derivative thereof is composed of The compound shown in formula 2 is prepared,
- R is hydrogen, C 1 -C 5 alkyl or benzyl; Indicates a single bond or a double bond, the position indicated by A and B is are independently selected from a single bond and a double bond, when When representing a single bond, R 1 or R 2 connected to the single bond is selected from one of p-toluenesulfonyl, p-toluenesulfinyl, benzenesulfonyl and benzenesulfinyl, when When representing a double bond, R 1 or R 2 connected to the double bond is hydrogen.
- R is selected from H, C 1 -C 5 alkyl
- the compound shown in the formula 2 is one of the compounds shown below,
- the biliverdin or its derivative is prepared from the compound represented by formula 2 through a heating reaction.
- the solvent used in the heating reaction is selected from one or more of substituted benzene, pyrrolidone, DMF and THF.
- the reaction yield can reach 45% and above.
- the solvent used in the heating reaction is selected from one or more of xylene, nitrobenzene, chlorobenzene, DMF and THF.
- the reaction temperature of the heating reaction is controlled to be 100-160°C.
- the reaction yield reaches more than 45%.
- the reaction temperature of the heating reaction is controlled to be 130-150°C.
- the reaction temperature is controlled at 130-150°C, the reaction is carried out in a preferred reaction solvent, and the reaction yield reaches 60% and above.
- a catalyst needs to be added during the preparation process.
- the catalyst is an organic base.
- the reaction temperature is controlled to be 130-150° C., and it is carried out in a preferred reaction solvent, the reaction yield reaches 70% and above.
- the organic base is selected from one or more of pyridine and sodium ethoxide.
- the reaction yield reached 73% and above.
- the biliverdin or its derivative is obtained by recrystallization and extraction.
- the solvent used in the recrystallization is selected from one or both of ethyl acetate and ethanol.
- the biliverdin or its derivatives are acidified and then extracted with dichloromethane to obtain
- the preparation method of biliverdin of the present invention or its derivative is simple in process, does not require column chromatography, has high yield and low cost, and is suitable for industrialized production;
- the preparation method of biliverdin or its derivatives of the present invention reduces the generation of biliverdin dimethyl ester or by-products close to the product and its structure in the synthesis of biliverdin, is easy to purify, and improves the product purity.
- the raw materials for synthesizing the compound represented by formula 3, the compound represented by formula 9 and formula 10, include the following experimental groups:
- the synthesis of the compounds represented by the raw material formula 15 and formula 16 of the synthesis formula 5 includes the following experimental groups:
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
- 根据权利要求1或2所述的胆绿素或其衍生物的制备方法,其特征在于,所述胆绿素或其衍生物由式2所示化合物经加热反应制备得到。
- 根据权利要求4所述的胆绿素或其衍生物的制备方法,其特征在于,所述加热反应所使用的溶剂选自取代苯、吡咯烷酮、DMF和THF中的一种或多种。
- 根据权利要求5所述的胆绿素或其衍生物的制备方法,其特征在于,所述加热反应所使用的溶剂选自二甲苯、硝基苯、氯苯、DMF和THF中的一种或多种。
- 根据权利要求4所述的胆绿素或其衍生物的制备方法,其特征在于,控制加热反应的反应温度为100~160℃。
- 根据权利要求1或2所述的胆绿素或其衍生物的制备方法,其特征在于,制备过程中需加入催化剂。
- 根据权利要求8所述的胆绿素或其衍生物的制备方法,其特征在于,所述催化剂为有机碱。
- 根据权利要求9所述的胆绿素或其衍生物的制备方法,其特征在于,所述有机碱选自吡啶、乙醇钠中的一种或两种。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023528162A JP2023548916A (ja) | 2020-12-22 | 2021-01-26 | ビリベルジン又はその誘導体の製造方法 |
EP21908278.1A EP4269389A1 (en) | 2020-12-22 | 2021-01-26 | Preparation method for biliverdin or derivative thereof |
US18/206,653 US20230312533A1 (en) | 2020-12-22 | 2023-06-07 | Method for preparing biliverdin or derivative thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011529380.X | 2020-12-22 | ||
CN202011529380.XA CN112624953B (zh) | 2020-12-22 | 2020-12-22 | 胆绿素或其衍生物的制备方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/206,653 Continuation-In-Part US20230312533A1 (en) | 2020-12-22 | 2023-06-07 | Method for preparing biliverdin or derivative thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022134260A1 true WO2022134260A1 (zh) | 2022-06-30 |
Family
ID=75321196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/073781 WO2022134260A1 (zh) | 2020-12-22 | 2021-01-26 | 胆绿素或其衍生物的制备方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230312533A1 (zh) |
EP (1) | EP4269389A1 (zh) |
JP (1) | JP2023548916A (zh) |
CN (1) | CN112624953B (zh) |
WO (1) | WO2022134260A1 (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109535057A (zh) * | 2018-11-07 | 2019-03-29 | 百顺药业有限公司 | 一种用胆绿素Ⅸα二酯制备高含量胆红素Ⅸα的方法 |
-
2020
- 2020-12-22 CN CN202011529380.XA patent/CN112624953B/zh active Active
-
2021
- 2021-01-26 JP JP2023528162A patent/JP2023548916A/ja active Pending
- 2021-01-26 EP EP21908278.1A patent/EP4269389A1/en active Pending
- 2021-01-26 WO PCT/CN2021/073781 patent/WO2022134260A1/zh active Application Filing
-
2023
- 2023-06-07 US US18/206,653 patent/US20230312533A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109535057A (zh) * | 2018-11-07 | 2019-03-29 | 百顺药业有限公司 | 一种用胆绿素Ⅸα二酯制备高含量胆红素Ⅸα的方法 |
Non-Patent Citations (11)
Title |
---|
ANGEW. CHEM. INT. ED., vol. 37, no. 13-14, 1998, pages 1843 - 1846 |
BULL. CHEM. SOC. JPN., vol. 67, 1994, pages 3088 - 3093 |
CHEM LETT., vol. 6, 2001, pages 590 - 591 |
E. D. STURROCKJ. R. BULLBR.E. KIRSCH, J. LABELED COMPD. RAD., 1994, pages 263 - 274 |
HAMMAM MOSTAFA A. S., NAKAMURA HIROSHI, HIRATA YUKARI, KHAWN HTOI, MURATA YASUE, KINOSHITA HIDEKI, INOMATA KATSUHIKO: "Syntheses of Biliverdin Derivatives Sterically Locked at the CD-Ring Components", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, CHEMICAL SOCIETY OF JAPAN,NIPPON KAGAKUKAI, JP, vol. 79, no. 10, 1 October 2006 (2006-10-01), JP , pages 1561 - 1572, XP055945542, ISSN: 0009-2673, DOI: 10.1246/bcsj.79.1561 * |
J. ORG. CHEM., vol. 85, 2020, pages 13015 - 13028 |
K. M. SMITHR. K. PANDEY, TETRAHEDRON, vol. 40, 1984, pages 1749 - 1754 |
KAKIUCHI TAKASHI, KINOSHITA HIDEKI, INOMATA KATSUHIKO: "Total Synthesis of (±)-Phytochromobilin Starting from Two Pyrrole Derivatives", SYNLETT, GEORG THIEME VERLAG, DE, vol. 1999, no. Sup. 1, 1 June 1999 (1999-06-01), DE , pages 901 - 904, XP055945973, ISSN: 0936-5214, DOI: 10.1055/s-1999-3105 * |
MONATSHR CHEM., vol. 120, 1989, pages 575 - 580 |
MORA MARÍA E, BARI SARA E, AWRUCH JOSEFINA, DELFINO JOSÉ M: "On how the conformation of biliverdins influences their reduction to bilirubins: A biological and molecular modeling study", BIOORGANIC, ELSEVIER, AMSTERDAM, NL, vol. 11, no. 21, 1 October 2003 (2003-10-01), AMSTERDAM, NL, pages 4661 - 4672, XP055945532, ISSN: 0968-0896, DOI: 10.1016/S0968-0896(03)00479-6 * |
TAKEDA SHUZO, ET AL.: "An Efficient Method for the Conversion of 2-Bromo-5-tosylpyrroles to the Corresponding 5-Tosylpyrrolinones as the D-Ring of Phycocyanobilin Derivatives", CHEMISTRY LETTERS, vol. 30, no. 6, 30 June 2001 (2001-06-30), pages 590 - 591, XP055945972, DOI: 10.1246/cl.2001.590 * |
Also Published As
Publication number | Publication date |
---|---|
US20230312533A1 (en) | 2023-10-05 |
CN112624953A (zh) | 2021-04-09 |
CN112624953B (zh) | 2023-07-21 |
EP4269389A1 (en) | 2023-11-01 |
JP2023548916A (ja) | 2023-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3966777A (en) | Process for the production of 1α-hydroxy provitamin D3 and 1α-hydroxy vitamin D3 | |
WO2022134261A1 (zh) | 胆绿素类化合物及其制备方法和用途 | |
WO2018205299A1 (zh) | 4,5-二取代-1-氢-吡咯(2,3-f)喹啉-2,7,9-三羧酸酯化合物及应用 | |
CN115417753B (zh) | 一种美利曲辛及其中间体的合成方法 | |
WO2022134260A1 (zh) | 胆绿素或其衍生物的制备方法 | |
US20070117982A1 (en) | Method for producing 1,2-unsaturated azasteroids | |
JPS6212772B2 (zh) | ||
JPS5829320B2 (ja) | スピロラクトンステロイド ノ シンキナ セイゾウホウ | |
KR0141482B1 (ko) | 0-카르복시피리딜-및 0-카르복시퀴놀릴이미다졸리논의 개선된 제조방법 | |
JPS5910674B2 (ja) | アポビンカミン酸エステルの製法 | |
Simpson | Two Simple Amidinium Vinylogs | |
JPS5850240B2 (ja) | アンドロスタン系の新規なジエン誘導体の製造法 | |
JP3264672B2 (ja) | α−トコフェロール−4−アミノ安息香酸エステル化合物及びその製造方法 | |
JPH07503008A (ja) | 3−アシルエストラトリエンおよびアシルベンゼンの製造方法 | |
JPH04364146A (ja) | ビタミンk4及びビタミンk4ジアセテートの製法 | |
US5003090A (en) | Process for the preparation of benzopyrans | |
JP3216912B2 (ja) | 2−アザビシクロ[2.2.1]ヘプト−5−エン−3−オンの製造法 | |
US4931574A (en) | Process for the preparation of benzopyrans | |
Abarca et al. | Triazolopyridines. Part 9. The synthesis of7-amino (1, 2, 3) triazolo (1, 5-a) pyridines | |
JPH05178884A (ja) | (+)−エストロン誘導体の製造法 | |
JPH03279343A (ja) | 環状ケトン類の製造方法 | |
JP3468211B2 (ja) | (+)−エストロン誘導体 | |
WO2023006986A1 (en) | Method for preparing and purifying an agent suitable for treating anemia | |
US4186138A (en) | Preparation of chroman-2-acetic acids | |
JPS61233645A (ja) | α−(3−クロロ−2−ブテニルオキシ)カルボン酸誘導体およびそれを製造する方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21908278 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023528162 Country of ref document: JP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023012367 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112023012367 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230621 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021908278 Country of ref document: EP Effective date: 20230724 |